Drug Overview
Pradaxa (dabigatran; Boehringer Ingelheim) is an orally available direct thrombin inhibitor (factor IIa inhibitor) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who previously received treatment with a parenteral anticoagulant for five to 10 days. Pradaxa acts by inhibiting the conversion of fibrinogen into fibrin during the coagulation cascade, and therefore does not allow for the stimulation of platelet activation. Further, through thrombin inhibition, Pradaxa prevents the development of thrombus. Taken together, the drug prevents the formation of blood clots.
Pradaxa (dabigatran; Boehringer Ingelheim) is an orally available direct thrombin inhibitor (factor IIa inhibitor) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who previously received treatment with a parenteral anticoagulant for five to 10 days. Pradaxa acts by inhibiting the conversion of fibrinogen into fibrin during the coagulation cascade, and therefore does not allow for the stimulation of platelet activation. Further, through thrombin inhibition, Pradaxa prevents the development of thrombus. Taken together, the drug prevents the formation of blood clots.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Pradaxa: Stroke prevention in atrial fibrillation (SPAF)
Pradaxa: Venous thromboembolism (VTE)
List of Figures
Figure 1: Pradaxa for SPAF - SWOT analysis
Figure 2: Drug assessment summary of Pradaxa for SPAF
Figure 3: Drug assessment summary of Pradaxa for SPAF
Figure 4: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Pradaxa for venous thromboembolism - SWOT analysis
Figure 6: Drug assessment summary of Pradaxa for venous thromboembolism
Figure 7: Drug assessment summary of Pradaxa for venous thromboembolism
Figure 8: Pradaxa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Pradaxa drug profile
Table 2: Pradaxa pivotal trial data in SPAF
Table 3: Pradaxa late-phase trial data in SPAF
Table 4: Pradaxa ongoing late-phase clinical trials in SPAF
Table 5: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Pradaxa drug profile
Table 7: Pradaxa pivotal trial data in venous thromboembolism
Table 8: Pradaxa late-phase trial data in venous thromboembolism
Table 9: Pradaxa ongoing late-phase clinical trials in venous thromboembolism
Table 10: Pradaxa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26
